11/14
04:05 pm
camp
CAMP4 Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Low
Report
CAMP4 Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
11/6
04:05 pm
camp
CAMP4 Reports Third Quarter 2025 Financial Results and Corporate Highlights
Medium
Report
CAMP4 Reports Third Quarter 2025 Financial Results and Corporate Highlights
10/1
08:00 am
camp
CAMP4 Therapeutics Initiates GLP Toxicology Studies for CMP-SYNGAP-01
Low
Report
CAMP4 Therapeutics Initiates GLP Toxicology Studies for CMP-SYNGAP-01
9/10
07:00 am
camp
CAMP4 Announces an Oversubscribed Private Placement of up to $100 Million to Advance First-in-Class Treatment for SYNGAP1-Related Disorders
High
Report
CAMP4 Announces an Oversubscribed Private Placement of up to $100 Million to Advance First-in-Class Treatment for SYNGAP1-Related Disorders